E-resources
Peer reviewed
Open access
-
Domachowske, Joseph; Madhi, Shabir A; Simões, Eric A.F; Atanasova, Victoria; Cabañas, Fernando; Furuno, Kenji; Garcia-Garcia, Maria L; Grantina, Ineta; Nguyen, Kim A; Brooks, Dennis; Chang, Yue; Leach, Amanda; Takas, Therese; Yuan, Yuan; Griffin, M. Pamela; Mankad, Vaishali S; Villafana, Tonya
The New England journal of medicine, 03/2022, Volume: 386, Issue: 9Journal Article
Nirsevimab is a monoclonal antibody targeting respiratory syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to receive palivizumab, including those born preterm (at 35 weeks of gestation or less) and those with congenital heart disease or chronic lung disease of prematurity. No safety concerns were identified.
